BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10623692)

  • 1. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells.
    Weaver CH; Schulman KA; Wilson-Relyea B; Birch R; West W; Buckner CD
    J Clin Oncol; 2000 Jan; 18(1):43-53. PubMed ID: 10623692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy.
    Weaver CH; Buckner CD; Curtis LH; Bajwa K; Weinfurt KP; Wilson-Relyea BJ; Schulman KA
    Bone Marrow Transplant; 2002 Jan; 29(2):159-64. PubMed ID: 11850711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
    Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.
    Perkins JB; Shapiro JF; Bookout RN; Yee GC; Anasetti C; Janssen WE; Fernandez HF
    Am J Hematol; 2012 Jul; 87(7):673-7. PubMed ID: 22674468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Heisrath-Evans J; Koczyk-Scripka K; Pashko S; Norgard MJ; Barnes HM; Taylor WR; Thompson KA; Smith LF; Ueno WM; Dobrzynski RF; Warren RD; Katcher D; Byrne PJ; Dunning DM; Winokur SH; Lockey JL; Cambareri RJ; Butler TP; Meister RJ; Fiegert JM
    Support Care Cancer; 1997 Jul; 5(4):289-98. PubMed ID: 9257425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
    J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.
    Weaver A; Chang J; Wrigley E; de Wynter E; Woll PJ; Lind M; Jenkins B; Gill C; Wilkinson PM; Pettengell R; Radford JA; Collins CD; Dexter TM; Testa NG; Crowther D
    J Clin Oncol; 1998 Aug; 16(8):2601-12. PubMed ID: 9704709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim.
    Weaver CH; Birch R; Greco FA; Schwartzberg L; McAneny B; Moore M; Oviatt D; Redmond J; George C; Alberico T; Johnson P; Buckner CD
    Br J Haematol; 1998 Feb; 100(2):338-47. PubMed ID: 9488624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.
    Glaspy JA; Shpall EJ; LeMaistre CF; Briddell RA; Menchaca DM; Turner SA; Lill M; Chap L; Jones R; Wiers MD; Sheridan WP; McNiece IK
    Blood; 1997 Oct; 90(8):2939-51. PubMed ID: 9376574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.
    Klein J; Rey P; Dansey R; Karanes C; Abella E; Cassells L; Hamm C; Flowers M; Couwlier C; Peters W; Baynes R
    Bone Marrow Transplant; 1999 Nov; 24(9):959-63. PubMed ID: 10556954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Harvey JH; Windsor K; Gore I; Cantrell J; Thompson KA; Taylor WR; Barnes HM; Schiff SA; Shields JA; Cambareri RJ; Butler TP; Meister RJ; Feigert JM; Norgard MJ; Moraes MA; Helvie WW; Patton GA; Mundy LJ; Henry D; Sheridan MJ
    Cancer Invest; 1998; 16(6):366-73. PubMed ID: 9679526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.